In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma.
Of Interest
Melanoma tumors thicker than 0.8 mm increase risk for death
The crude incidence rate of melanoma-related death 20 years after diagnosis was 6% for those with tumors thinner than 0.8 mm.
Tumor Upstaging in Invasive Melanoma Linked to Worse Survival Outcomes
Shortfalls in clinical management may explain why tumor upstaging in invasive melanoma is associated with worse survival outcomes, according to study findings published in the Journal of the American Academy of Dermatology.
mmune Checkpoint Inhibitors for Advanced Melanoma: 10-Year Outcomes Turn Heads
The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but their immune targets differ.